SINCE 2014, SEN-JAM HAS BEEN ON A MISSION TO REVOLUTIONIze INFLAMMATORY CARE - AND usher in a new dawn for humanity... FULL-STRENGTH LIVING

Press Release

Sen-Jam’s press release hit the newsfeeds with the announcement of our Phase 2 Clinical trial beginning for SJP-001, Alcohol Hangover. 

Webinar on Self-Directed IRA Funding for Crowdfunding Campaigns

Most people don’t realize that IRAs in the U.S. now hold $14.5 trillion in assets, with 43% of those investments allocated to mutual funds. More individuals are leveraging Self-Directed IRAs to diversify their retirement savings into non-traditional opportunities, including crowdfunding,​ and this webinar - led by our CEO and featuring a guest expert custodian for such transactions, will help you understand what’s involved. HERE is the recording.

NIDA completes first round of studies

The National Institute of Drug Abuse (NIDA) has just completed the first round of studies in partnership with us, and once the second round is done, we anticipate exceptional progress.

Sen-Jam Boston Life Science Innovator Conference Attendance

Executive Team attended the LSX conference in Boston, where they engaged with investors and life science innovators to advance our mission. 

"Stronger Together" Campaign

Our “STRONGER TOGETHER” Webinar, tackling Addiction as Allies, co-hosted with Sen-Jam and Loosid, the world’s best social network for sober living, was a huge success. If you missed it, you can rewatch the recording HERE! 

Entrepreneur Prime UK Feature

Jackie Iversen RPh MS, Co-Founder, and Sen-Jam’s visionary Chief Clinical Officer was interviewed by “Entrepreneur Prime UK”, a leading business magazine out of London that features world-class leaders who are changing the landscape of their industries. Please enjoy reading that piece HERE.

Buck Institute Visit

The Founders also flew to the San Fran area mid-month to meet with a few high-roller investors and health transformers including a second visit with colleagues at The Buck Institute, 

CONNECTpreneur Session

Jim Iversen, CEO and Co-Founder of Sen-Jam presents. Watch HERE. 

Bio San Diego Conference

Sen-Jam Leadership Team attended this industry conference meeting with potential partners.

Press Release

Announcing Upcoming Completion of Phase 2 Clinical Trials.

Article Published

Pharma Industrial India publishes an article on global advances at Sen-Jam Pharmaceutical.

Industry Speaker

Co-Founder, Chief Clinical Officer, Jackie Iversen RPh MS spoke in London at the 14th Annual CB&CDx Europe conference.

Industry Speaker

Co-Founder, Chief Clinical Officer, Jackie Iversen RPh MS  speaks to thought leaders in New York City’s MedInvest Conference.

Intellectual Property Update

SJP-001 Patent for Canada, increasing the total number of countries covered by our intellectual property for this asset to 22.

Fireside Chat

Kingscrowd interviews Co-Founder, Chief Clinical Officer, Jackie Iversen RPh MS.

Executive Webinar

Post JPMorgan Healthcare Conference Insights Executive webinar: Weight Loss, Ozempic, & Inflammation

2024

Executive Webinar

Executive Webinar: Unpacking the Business Model

Executive Webinar

Executive Webinar: Precision Medicine: Changing the Course of Inflammation For Good

Article Published

Co-Founder/CCO Jackie Iversen RPh MS publishes article on Rethinking the Medicine Cabinet in Pharmacy Times

Company Anniversary

SJP celebrates it’s 6th Birthday

Fireside Chat 

Sen-Jam’s CCO on Podcast with MJ Gottlieb, the Co-Founder and CEO of Loosid, the world's most popular sobriety app.

Article Published

How A Rebirth Towards Preventing Inflammation Will Positively Impact Age-Related Diseases in Pharmacy Times by Jackie Iversen RPh MS

Intellectual Property Update

Secured two more patents worldwide with Mexico and Israel for SJP001 (Alcohol Hangover Prevention therapeutic)

Meet the Founder Webinar 

World-renowned Physicist, Investor and Advisor, Alexander Wissner-Gross hosts a Sen-Jam Pharma Webinar. See it HERE.

Article Published 

Connecting the Dots of Alcohol Hangover, Inflammation and Age-Related Diseases in Pharmacy Times by Jackie Iversen, RPh MS

SJP Sponsoring Students at Northeastern 

Students involved in the Capstone Project at Northeastern University presented their final reports to the Sen-Jam Team

JP Morgan 41st Annual Conference

Jackie Iversen RPh, MS, spoke at the 41st Annual JP Morgan Health Conference in San Francisco. and the Team met with many interested investors.

2023

Fireside Chat with Real Leaders

Sen-Jam CEO, Jim Iversen shares the mic with Kiran Vepuri, KVK Tech's VP of Business Development. "ARE YOU A DISRUPTER?" fireside chat  on the power of collaboration and innovative thinking to get things done faster and more efficiently, together. To see Kiran's quick 4-minute recap from this event, click HERE.

Capital Campaign

Launch on STARTENGINE for Series A Funding open to both Individual and Institutional Investors

Study Published

SJP-003 Peer Review Study Published on the Adverse Effects of Vaccine Administration

Webinar

Investor Roundtable Webinar with Distinguished Panelists

Clinical Trail Commences

Clinical Trial Enrollment Officially Underway in Nepal for our COVID-19 Therapeutic

Intellectual Property Update

Alcohol Hangover Prevention asset SJP-001 awarded European Patent

Press Release

SJP enters Powerful Partnership with CMC
expert, KVK-Tech

Press Release

NHRC commences COVID-19 clinical trials

Post

The case for the balanced beauty of repurposing established drugs in novel combination: Is Big Pharma overlooking the goldilocks solutions right under our nose?

Post

The Fight to Treat COVID: Sorting through therapeutics, from anti-virals to anti-inflammatories

2022

COVID-19 Phase II Clinical Trial Secured

Press Release: Sen-Jam Pharmaceutical secures Phase II Clinical Trial for COVID therapy SEN-JAM PR Oct 12 2021 Pill for COVID treatment Trials

Novel Solutions for Addressing Traditional Treatment Deficits

Press Release: Sen-Jam Pharmaceuticals addresses deficits with traditional treatments for COVID-19 as well as OPIOID WITHDRAWAL SEN-JAM PR Sept 28 2021 COVID Treatment

Press Release

Sen-Jam Pharmaceutical Partners With Duke-NUS Medical School for a Phase 2 Trial for a New COVID 19 Treatment

Intellectual Property Update

Australian Patent Granted AU2016235484B2 for Methods and Compositions to Inhibit Symptoms Associated with Veisalgia (SJP-001) (Alcohol Hangover Prevention)

Intellectual Patent Update

South Africa Patent Granted 201706794B for Methods and Compositions to Inhibit Symptoms Associated with Veisalgia (SJP-001) (Alcohol Hangover Prevention)

Licensing Update

Sen-Jam has executed a licensing term sheet with Haltzak Biopharma for SJP-002C (COVID-19 Treatment) for Colombia with expansion rights to Central and South America.

Opioid Withdrawal Research Papers Published

Functional observation after morphine withdrawal: effects of SJP-005

A Comparison of the Antinociceptive Properties of SJP-005 and Morphine in Rats

2021

Licensing Update

Sen-Jam has executed a licensing term sheet with Haltzak Biopharma for SJP-001 (Hangover Prevention) for Colombia with expansion rights to Central and South America.

Intellectual Property Update

US Patent Award No. 10,675,261 for Methods and Compositions to Inhibit Dependence of Opioids (SJP-006)

In-Vitro Study underway testing SJP-002 against the COVID-19 virus

Listed on RedCrow’s Equity CrowdFunding site

Sen-Jam featured in StartUp Healths Insights

Off-Label use of our Opioid Withdrawal Product used in tapering Suboxone

Sen-Jam attends RESI conference and pushes greater insight on Opioid Use Disorder

Patent issued for SJP-001

Partnered with Stony Brook University - Center for Biotechnology

Sen-Jam participates in StartUp Health Festival, the premier forum of Health Transformers during JP Morgan Health Conference

2019

Sen-Jam attends Research Society on Alcoholism Conference

Spring pre-clinical studies for opioid withdrawal (SJP-005)

Sen-Jam attends JP Morgan Health Conference

2018

Sen-Jam first Corporate Retreat

Sen-Jam files patent to inhibit adverse effects associated with vaccinations (SJP-003)

Sen-Jam attends Research Society on Alcoholism Conference

Sen-Jam files patent to inhibit symptoms associated with Viral Respiratory Infections (SJP-002)

Sen-Jam completes Pre-Investigational new drug meeting with FDA

Sen-Jam presents findings to Alcohol Hangover Research Group at National Institute on Alcohol Abuse and Alcoholism Conference

Provisional Patents Filed

2015

Jackie Iversen has Eureka moment

2014